Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

High Risk

Score: 65/100

Failure Rate

22.2%

2 terminated/withdrawn out of 9 trials

Success Rate

77.8%

-8.7% vs industry average

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

57%

4 of 7 completed trials have results

Key Signals

4 with results

Enrollment Performance

Analytics

Early Phase 1

3(33.3%)

Phase 2

3(33.3%)

N/A

2(22.2%)

Phase 1

1(11.1%)

9Total

Early Phase 1(3)

Phase 2(3)

N/A(2)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (9)

Showing 9 of 9 trials

NCT06371521Phase 1Completed

Ergogenic Effects of Sportlegs

Role: lead

NCT05285449Not ApplicableCompleted

Influence of Cannabidiol on Glucose Tolerance and The Gut Microbiota

Role: lead

NCT06011265Early Phase 1Completed

Does Mirabegron Increase the Body Heat Generated by the Nervous System

Role: lead

NCT05282693Not ApplicableCompleted

Ergogenic Properties of Magnesium Supplementation

Role: lead

NCT05192239Early Phase 1Completed

Influence of Edible Marijuana on Endurance Exercise Performance

Role: lead

NCT04870801Early Phase 1Withdrawn

An Alternative Way To Deliver Oxygen To People

Role: lead

NCT03180489Phase 2Completed

Does Dapagliflozin Provide Additional Health Benefits To Dietary Counseling For Weight Loss?

Role: lead

NCT02371187Phase 2Completed

Does Dapagliflozin Augment The Favorable Adaptation To Endurance Exercise Training?

Role: lead

NCT02520518Phase 2Terminated

Does Dapagliflozin Promote Favorable Health Benefits That Are Independent Of Weight Loss?

Role: lead

All 9 trials loaded